Trastuzumab duocarmazine（Cat No.:I042125）is an antibody-drug conjugate (ADC) that combines trastuzumab, a monoclonal antibody targeting HER2 (human epidermal growth factor receptor 2), with a cytotoxic agent. This drug targets HER2-positive cancer cells, commonly seen in breast cancer and gastric cancer, delivering the cytotoxic agent directly to the tumor. The conjugate works by binding to HER2 on cancer cells and releasing the chemotherapy drug, which induces cell death. Clinical trials have shown promising results, and it is being investigated as a treatment for patients with advanced or metastatic HER2-positive cancers.
